IMAGE SOURCE: BRON766 VIA WIKIMEDIA COMMONS.
Continue Reading Below
What:As it's done so many times recently,Exelixis ended down 10.4% on Tuesday on seemingly no news.
So what: It's the curse of the biotechs that have a majority of their value tied up in their pipelines. One day investors might love them, the next they might hate them.
Don't like the current situation? Just wait a few days.
In fact, Exelixis traded at the level it closed on Tuesday a few weeks ago. And last week, the stock closed higher and lower than Monday's close. The stock chart looks like an EKG reading.
Now what: Long-term investors needn't worry about the short-term changes in valuations. Sure it hurts on double-digit down says -- and is great on double-digit up days -- but the moves shouldn't have much effect on Exelixis' long-term value.
Years from now, we'll be talking about the sales of cabozantinib for kidney cancer -- and perhaps liver cancer as well -- rather than the daily gyrations of the stock price.
The schizophrenic stock chart could be because investors are worried about whethercabozantinib will be approved by U.S. and EU regulators, but it seems more likely they're confident in an approval but worried about the potential sales givenBristol-Myers Squibb's quick approval of Opdivo for kidney cancer. That Exelixis hasn't released the overall survival data, which would help investors compare the efficacy of the two, makes it hard for investors to know whether Exelixis or Bristol-Myers Squibb will be able to win the battle for kidney cancer patients.
The article Exelixis, Inc.'s EKG-Like Stock Chart Hits a Low Spot originally appeared on Fool.com.
Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.